LYELLyell Immunopharma Inc
$13.11
$0.19
(1.47%)
Closed $13.11
$0.00
(0.00%)
After Hours
EarningsAug 14
Mkt Cap$316.6M
Vol151,301.00
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advances study to Phase 1/2 design.read more...
Benzinga
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday
Lyell Immunopharma (NASDAQ:LYEL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-lyell-immunopharma-inc-stock...
MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have iss...
MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Lyell Immunopharma from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down - Here's What Happened
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down - Here's What Happened...
MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest
Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totaling 1,138,296 shares, a...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest LYEL News
ViewWall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
Zacks
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
Benzinga
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks
Advertisement|Remove ads.